SPEAKERS
Dr. Quynh Doan is a Clinician scientist in pediatric emergency Medicine. Her primary research interests are in health services, and while she engages in clinical trials, she focuses on outcome measures related to impacts to the health system and healthcare utilization.
She is also the senior executive director of the BC Children’s Hospital Research Institute, and UBC Associate Dean, Research for the Institute. In this role, she has focused her efforts to implement IDEAA principles to the research conducted at the BCCHRI, through evaluation of current states with regard to the inclusion of a diverse research population in an equitable manner and introduce solutions to facilitate culture and practice changes.
Session: Diversity & Inclusion in Pediatric Research, From Ideation to Implementation
Dr. Wendy London is a Professor of Pediatrics, Harvard Medical School, and the Director of Biostatistics in the Division of Pediatric Hematology/Oncology at Dana-Farber Cancer Institute and Boston Children’s Hospital. She is the Director of the Survey and Qualitative Methods Core, Dana-Farber/ Harvard Cancer Center. Dr. London was awarded her PhD in Biostatistics from Virginia Commonwealth University, Medical College of Virgina, in 1997. She has >25 years of experience in design, conduct, analysis, and reporting of clinical trials and biological studies in pediatric cancer. Dr. London serves as a member of the Children’s Oncology Group (COG) Neuroblastoma Steering Committee, and was Lead Statistician for the COG Neuroblastoma Committee (1998-2014). She collaborated/designed/conducted phase 3 trials in high-risk neuroblastoma that set a new standard of care: FDA approval of the immunotherapy, dinutuximab, and superiority of two autologous stem cell transplants. Dr. London was instrumental in developing the COG Neuroblastoma Virtual Tumor Bank of specimen, biology, and outcome data, and developed automated systems for assigning risk group (treatment intensity).
Dr. London’s research focuses on the identification of prognostic biomarkers in neuroblastoma, and applying them to create and improve risk stratification for the assignment of treatment intensity for children with neuroblastoma, at diagnosis and relapse. She chairs the Statistics Committee of the International Neuroblastoma Risk Groups (INRG) task force, where she collaborated to develop a global system for pre-treatment risk stratification and the INRG Data Commons.
Dr. London is a member of the Cellular, Tissue, and Gene Therapies Advisory Committee of the Food and Drug Administration (2023-27) and the NIH/NCI Therapeutic Immune Regulation (TIR) Study Section (2022-26). She served as a permanent member of the NIH/NCI Clinical Oncology Study Section (2006-10), on NIH/NCI Immunotherapy Study Section (2022-23), on NIH/NCI Subcommittee H in review of the cancer cooperative groups, and on the American Society of Clinical Oncology (ASCO) program committee (2014-16). She is a member of the editorial board of the Journal of the National Cancer Institute (2020-present), and was a member of the Journal of Clinical Oncology editorial board from 2013-2020. She has been a faculty member of the American Association for Cancer Research/American Society of Clinical Oncology (AACR/ASCO) Methods in Clinical Cancer Research Workshop since 2011, and is currently a workshop co-chair (2024-26).
Session: Statistical efficiencies – choosing the right methods for the right question
Dr. Michaël Chassé
Intensivist, University of Montreal Hospital Center
Associate Professor, Department of Medicine, University of Montreal
Scientific Director, CHUM Data Integration and Analysis Center
Deputy Scientific Director, Data Science, CRCHUM
Session: AI in Clinical Trials